Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6800730 | Journal of Psychiatric Research | 2015 | 9 Pages |
Abstract
For depressed patients without PPS, SSRIs are likely to be cost-effective in improving remission rates and QALYs compared to TCAs and SNRIs. However, to improve cost-utility in those with comorbid PPS, people need to choose between SSRIs and TCAs according to threshold willingness-to-pay levels. Future research is warranted to clarify the impacts of different pain conditions on the economic evaluations of pharmacological treatments in patients with depression.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Yi-Ju Pan, Chun-Hao Pan, Hung-Yu Chan, Kuei-Hong Kuo,